{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:11:57Z","timestamp":1762521117823},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.transproceed.2006.10.107","type":"journal-article","created":{"date-parts":[[2006,12,16]],"date-time":"2006-12-16T12:14:37Z","timestamp":1166271277000},"page":"3552-3555","source":"Crossref","is-referenced-by-count":43,"title":["Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy"],"prefix":"10.1016","volume":"38","author":[{"given":"G.W.","family":"Neff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.C.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"McHenry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Novick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Buell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2006.10.107_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials","volume":"328","author":"Als-Nielsen","year":"2004","journal-title":"BMJ"},{"issue":"suppl 2","key":"10.1016\/j.transproceed.2006.10.107_bib2","first-page":"14","article-title":"Treatment of hepatic encephalopathy with non-absorbable antibiotics","volume":"24","author":"Festi","year":"1992","journal-title":"Ital J Gastroenterol"},{"issue":"suppl","key":"10.1016\/j.transproceed.2006.10.107_bib3","first-page":"1","article-title":"[Branched-chain amino acids and their therapeutic use]","year":"1992","journal-title":"Internist (Berl)"},{"key":"10.1016\/j.transproceed.2006.10.107_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11011-005-7205-0","article-title":"Ammonia and hepatic encephalopathy: the more things change, the more they remain the same","volume":"20","author":"Shawcross","year":"2005","journal-title":"Metab Brain Dis"},{"issue":"4","key":"10.1016\/j.transproceed.2006.10.107_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/B:MEBR.0000043979.58915.41","article-title":"Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint","volume":"19","author":"Ahboucha","year":"2004","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.transproceed.2006.10.107_bib6","first-page":"37","article-title":"Alpha-ketoglutarmate, glutamate antagonism and GABA depletion\u2014clues to the pathogenesis of hepatic encephalopathy?","volume":"17","author":"Kardel","year":"1974","journal-title":"Neth J Med"},{"key":"10.1016\/j.transproceed.2006.10.107_bib7","first-page":"61","article-title":"Brain energy metabolism and alterations of transmitter profiles in acute hepatic coma","author":"Funovics","year":"1978","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.transproceed.2006.10.107_bib8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1471-4159.1982.tb07893.x","article-title":"Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats","volume":"38","author":"Zeneroli","year":"1982","journal-title":"J Neurochem"},{"key":"10.1016\/j.transproceed.2006.10.107_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hep.1840080114","article-title":"Overestimation of serum concentrations of gamma-aminobutyric acid in patients with hepatic encephalopathy by the gamma-aminobutyric acid-radioreceptor assay","volume":"8","author":"Ferenci","year":"1988","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2006.10.107_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000081994","article-title":"Management of hepatic encephalopathy: role of rifaximin","volume":"51","author":"Zeneroli","year":"2005","journal-title":"Chemotherapy"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2006.10.107_bib11","first-page":"10","article-title":"Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety","volume":"5","author":"Williams","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2006.10.107_bib12","first-page":"3","article-title":"Role of antibiotics in the management of hepatic encephalopathy","volume":"5","author":"Maddrey","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2006.10.107_bib13","first-page":"1","article-title":"Role of antibiotics in hepatic encephalopathy: current status and future directions","volume":"5","author":"Maddrey","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.transproceed.2006.10.107_bib14","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0140-6736(05)66366-0","article-title":"Treatment of hepatic encephalopathy","volume":"365","author":"Cordoba","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2006.10.107_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(05)66365-9","article-title":"Treatment of hepatic encephalopathy","volume":"365","author":"Blei","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2006.10.107_bib16","first-page":"377","article-title":"The treatment of chronic hepatic encephalopathy","volume":"38","author":"Morgan","year":"1991","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.transproceed.2006.10.107_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(05)17832-5","article-title":"Dispelling myths in the treatment of hepatic encephalopathy","volume":"365","author":"Shawcross","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2006.10.107_bib18","first-page":"50","article-title":"[Cost of of hospital management of cirrhoses and its complications at the University Hospital of Brazzaville]","volume":"64","author":"Atipo-Ibara","year":"2004","journal-title":"Med Trop (Mars)"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2006.10.107_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.transproceed.2006.10.107_bib20","first-page":"387","article-title":"A non-absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa","year":"1985","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.transproceed.2006.10.107_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042737-200012020-00012","article-title":"Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study","volume":"12","author":"Williams","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2006.10.107_bib22","first-page":"161","article-title":"Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study","volume":"31","author":"Venturini","year":"2005","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.transproceed.2006.10.107_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.transproceed.2006.10.107_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/0036552031000-762","article-title":"Intractable hepatic encephalopathy after tips with polytetrafluoroethylene-covered stent-graft","volume":"38","author":"Riggio","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.transproceed.2006.10.107_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy","volume":"13","author":"Miglio","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transproceed.2006.10.107_bib26","first-page":"403","article-title":"Rifaximine versus neomycin in the treatment of portosystemic encephalopathy","volume":"23","author":"Di Piazza","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.transproceed.2006.10.107_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134506013364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134506013364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T19:59:58Z","timestamp":1547150398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134506013364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0041134506013364"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2006.10.107","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}